Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice

Zhuo,Meng; Song,Linlin; Tang,Yuyan; Dai,Shenglan; Chen,Xiaohua; Yu,Yongsheng; Zang,Guoqing; Tang,Zhenghao

doi:10.3892/mmr.2015.3834

Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice

Authors:
- Meng Zhuo
- Linlin Song
- Yuyan Tang
- Shenglan Dai
- Xiaohua Chen
- Yongsheng Yu
- Guoqing Zang
- Zhenghao Tang
View Affiliations

Affiliations: Department of Infectious Disease, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China
Published online on: May 25, 2015 https://doi.org/10.3892/mmr.2015.3834
Pages: 3591-3598

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic hepatitis B virus (HBV) infection is characterized by functionally impaired type 1 T-helper cell (Thl) immunity and poor HBV‑specific T‑cell responses. Ubiquitin (Ub), a highly conserved small regulatory protein, commonly serves as a signal for target proteins that are recognized and degraded in proteasomes. The rapid degradation of Ub‑mediated antigens results in efficient stimulation of cell‑mediated immune responses. Thus, the Ub‑HBV core antigen (HBcAg)‑cytoplasmic transduction peptide (CTP) fusion protein was designed for specific delivery of a foreign modified antigen to the cytoplasm of antigen‑presenting cells. HBV transgenic mice were used to determine whether Ub‑HBcAg‑CTP would restore HBV‑specific immune responses and anti‑viral immunity in these animals. The results demonstrated that synthesized Ub‑HBcAg‑CTP not only significantly increased the levels of interleukin‑2 and interferon (IFN)‑γ compared with those in the HBcAg‑CTP, IFN‑α, Ub‑HBcAg, HBcAg and phosphate‑buffered saline groups, but additionally induced the highest IFN‑γ+ CD8+ T‑cell numbers and HBV‑specific cytotoxic T lymphocyte (CTL) responses, indicating a strong immune response. In addition, enhancement of specific CTL activity provoked by the fusion protein reduced hepatitis B surface antigen (HBsAg) and HBV DNA serum levels and diminished the expression of HBsAg and HBcAg in liver tissue of HBV transgenic mice, suggesting that there was a therapeutic effect. In conclusion, the present study provided evidence that Ub‑HBcAg‑CTP activated the Th1‑dependent immunity, triggered functional T cell responses and subsequently inhibited viral replication in HBV transgenic mice. These observations suggested that the fusion protein may represent an innovative and promising candidate for active immunotherapy during chronic and persistent HBV.

View Figures

View References

1	Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL and Kowdley KV: Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 38:S158–S168. 2004. View Article : Google Scholar : PubMed/NCBI
2	Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
3	Buchmann P, Dembek C, Kuklick L, et al: A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine. 31:1197–1203. 2013. View Article : Google Scholar : PubMed/NCBI
4	Rehermann B: Immune responses in hepatitis B virus infection. Semin Liver Dis. 23:21–38. 2003. View Article : Google Scholar : PubMed/NCBI
5	Baumert TF, Thimme R and Von Weizsacker F: Pathogenesis of hepatitis B virus infection. World J Gastroenterol. 13:82–90. 2007. View Article : Google Scholar : PubMed/NCBI
6	Thimme R, Wieland S, Steiger C, et al: CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 77:68–76. 2003. View Article : Google Scholar :
7	Chen W, Shi M, Shi F, et al: HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes. Hepatol Res. 39:355–365. 2009. View Article : Google Scholar : PubMed/NCBI
8	Yang BF, Zhao HL, Xue C, et al: Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response. Vaccine. 25:4478–4486. 2007. View Article : Google Scholar : PubMed/NCBI
9	Tang Y, Chen X, Zhang Y, et al: Fusion protein of tapasin and hepatitis B core antigen 18–27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice. Mol Med Rep. 9:1171–1178. 2014.PubMed/NCBI
10	Kim D, Jeon C, Kim JH, et al: Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res. 312:1277–1288. 2006. View Article : Google Scholar : PubMed/NCBI
11	Song L, Zhuo M, Tang Y, Chen X, Yu Y, Tang Z, et al: Ubiquitin-modified hepatitis B virus core antigen effectively facilitates antigen presentation and enhances cytotoxic T lymphocyte activity via the cytoplasmic transduction peptide invitro. Mol Med Rep. 12:289–296. 2015.PubMed/NCBI
12	Kerscher O, Felberbaum R and Hochstrasser M: Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol. 22:159–180. 2006. View Article : Google Scholar : PubMed/NCBI
13	Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature. 426:895–899. 2003. View Article : Google Scholar : PubMed/NCBI
14	Bandi P, Garcia ML, Booth CJ, Chisari FV and Robek MD: Bortezomib inhibits hepatitis B virus replication in transgenic mice. Antimicrob Agents Chemother. 54:749–756. 2010. View Article : Google Scholar :
15	Loureiro J and Ploegh HL: Antigen Presentation and the ubiquitin-proteasome system in host-pathogen interactions. Adv Immunol. 92:225–305. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kerscher O, Felberbaum R and Hochstrasser M: Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol. 22:159–180. 2006. View Article : Google Scholar : PubMed/NCBI
17	Welchman RL, Gordon C and Mayer RJ: Ubiquitin and ubiq-uitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 6:599–609. 2005. View Article : Google Scholar : PubMed/NCBI
18	Song L, Zhuo M, Tang Y, Chen X, Tang Z and Zang G: Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo. International Immunopharmacology. 23:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
19	Chen JH, Yu YS, Chen XH, Liu HH, Zang GQ and Tang ZH: Enhancement of CTLs induced by DCs loaded with ubiqui-tinated hepatitis B virus core antigen. World J Gastroenterol. 18:1319–1327. 2012. View Article : Google Scholar : PubMed/NCBI
20	Guidotti LG, Matzke B, Schaller H and Chisari FV: High-level hepatitis B virus replication in transgenic mice. J Virol. 69:6158–6169. 1995.PubMed/NCBI
21	Crawford TQ, Ndhlovu LC, Tan A, et al: HIV-1 infection abrogates CD8+T cell mitogen-activated protein kinase signaling responses. J Virol. 85:12343–12350. 2011. View Article : Google Scholar : PubMed/NCBI
22	Lycke NY and Coico R: Measurement of immunoglobulin synthesis using the ELISPOT assay. Curr Protoc Immunol. 14:2001. View Article : Google Scholar
23	Chen X, Lai J, Pan Q, Tang Z, Yu Y and Zang G: The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice. Vaccine. 28:3913–3919. 2010. View Article : Google Scholar : PubMed/NCBI
24	Huang Y, Chen Z, Jia H, Wu W, Zhong S and Zhou C: Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg. Clin Immunol. 119:280–290. 2006. View Article : Google Scholar : PubMed/NCBI
25	Boni C, Fisicaro P, Valdatta C, et al: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 81:4215–4225. 2007. View Article : Google Scholar : PubMed/NCBI
26	Deng Q, Mancini-Bourgine M, Zhang X, et al: Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models. Hepatology. 50:1380–1391. 2009. View Article : Google Scholar : PubMed/NCBI
27	Neefjes J, Jongsma ML, Paul P and Bakke O: Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 11:823–836. 2011.PubMed/NCBI
28	Tavakoli S, Mederacke I, Herzog-Hauff S, et al: Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clin Exp Immunol. 151:61–70. 2008. View Article : Google Scholar
29	Op den Brouw ML, Binda RS, Van Roosmalen MH, et al: Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology. 126:280–289. 2009. View Article : Google Scholar :
30	Chen X, Liu H, Tang Z, Yu Y and Zang G: The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracel-lularly delivered CTL epitopes via cytoplasmic transduction peptide. Acta Biochim Biophys Sin (Shanghai). 45:203–212. 2013. View Article : Google Scholar
31	Das A, Hoare M, Davies N, et al: Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med. 205:2111–2124. 2008. View Article : Google Scholar : PubMed/NCBI
32	Chamoto K, Kosaka A, Tsuji T, et al: Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci. 94:924–928. 2003. View Article : Google Scholar : PubMed/NCBI
33	Tsai SL, Sheen IS, Chien RN, et al: Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci. 10:120–135. 2003. View Article : Google Scholar : PubMed/NCBI
34	Boni C, Bertoletti A, Penna A, et al: Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 102:968–975. 1998. View Article : Google Scholar : PubMed/NCBI
35	Kosinska AD, Johrden L, Zhang E, et al: DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol. 86:9297–9310. 2012. View Article : Google Scholar : PubMed/NCBI
36	Seifert U and Krüger E: Remodelling of the ubiq-uitin-proteasome system in response to interferons. Biochem Soc Trans. 36:879–884. 2008. View Article : Google Scholar : PubMed/NCBI
37	Varshavsky A: The N-end rule. Cell. 69:725–735. 1992. View Article : Google Scholar : PubMed/NCBI
38	Ciechanover A and Ben-Saadon R: N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol. 14:103–106. 2004. View Article : Google Scholar : PubMed/NCBI
39	Rock KL and Goldberg AL: Degradation of cell proteins and the generation of MHC class I-presented peptides. Ann Rev Immunol. 17:739–779. 1999. View Article : Google Scholar
40	Rodriguez F, Zhang J and Whitton JL: DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol. 71:8497–8503. 1997.PubMed/NCBI
41	Liu Y, Testa JS, Philip R, Block TM and Mehta AS: A ubiquitin independent degradation pathway utilized by a hepatitis B virus envelope protein to limit antigen presentation. PLoS One. 6:e244772011. View Article : Google Scholar : PubMed/NCBI
42	Roh S and Kim K: Overcoming tolerance in hepatitis B virus transgenic mice: a possible involvement of regulatory T cells. Microbiol Immunol. 47:453–460. 2003. View Article : Google Scholar : PubMed/NCBI
43	Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y and Onji M: Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral Res. 96:59–64. 2012. View Article : Google Scholar : PubMed/NCBI